| Literature DB >> 32578854 |
Yuan Liu1,2, Yusheng Dou3, Liang Yan1, Xiaobin Yang1, Baorong He1, Lingbo Kong1, Wanli Smith4.
Abstract
Recently, Rho GTPases substrates include Rac (Rac1 and Rac2) and Cdc42 that have been reported to exert multiple cellular functions in osteoclasts, the most prominent of which includes regulating the dynamic actin cytoskeleton rearrangements. In addition, natural products and their molecular frameworks have a long tradition as valuable starting points for medicinal chemistry and drug discovery. Although currently, there are reports about the natural product, which could play a therapeutic role in bone loss diseases (osteoporosis and osteolysis) through the regulation of Rac1/2 and Cdc42 during osteoclasts cytoskeletal structuring. There have been several excellent studies for exploring the therapeutic potentials of various natural products for their role in inhibiting cancer cells migration and function via regulating the Rac1/2 and Cdc42. Herein in this review, we try to focus on recent advancement studies for extensively understanding the role of Rho GTPases substrates Rac1, Rac2 and Cdc42 in osteoclastogenesis, as well as therapeutic potentials of natural medicinal products for their properties on the regulation of Rac1, and/or Rac2 and Cdc42, which is in order to inspire drug discovery in regulating osteoclastogenesis.Entities:
Keywords: Cdc42; Rac; Rac1; Rho GTPase; bone; natural compounds
Mesh:
Substances:
Year: 2020 PMID: 32578854 PMCID: PMC7364480 DOI: 10.1042/BSR20200407
Source DB: PubMed Journal: Biosci Rep ISSN: 0144-8463 Impact factor: 3.840
Figure 1The schematic of osteoclastogenesis
The cytokines M-CSF and RANKL (from osteoblasts) bind to its receptors cFms and RANKL present in osteoclast precursors, respectively. Then the M-CSF stimulates osteoclast precursors proliferation and inhibits their apoptosis. Besides that, RANKL interacts with its receptor RANK in osteoclast precursor cells, then osteoclastognesis is induced.
The source, structure, cells or animal models and mechanisms of ten natural compounds
| Compound name | Source | Structure | Cell lines used for | Animal models | Dose | Mechanisms | Studies |
|---|---|---|---|---|---|---|---|
| Fisetin | Neuron | Wistar rats | 30 mg/kg | Rac1/Cdc42 | Jacob [ | ||
| Deacetyl- mycoepoxydiene | Human breast cancer MCF-7 cells | BABL/c mice | 5, 10, 20 mg/kg | Rac1 | Zhao [ | ||
| Diallyl disulfide | Human gastric cancer MGC803 cell line | BALB/c nude mice | 100mg/kg | Rac1 | Su [ | ||
| Plectranthoic acid | Prostate cancer cell lines (DU145, PC3, NA22, NB26) | N/A | N/A | Rac1 | Akhtar [ | ||
| Cudraxanthone S | N/A | N/A | N/A | Cdc42 | Gopal [ | ||
| Panacis Japonici Rhizoma | A2780 cell line | N/A | N/A | Cdc42 | Chen [ | ||
| Triptolide | Sprague–Dawley (SD) rats | Sprague–Dawley (SD) rats | 100 mg/kg | Rac1, Cdc42 | Wang [ | ||
| TDB (4,5,40-trihydroxy-3, 30- dimethoxybibenzy) | Human lung cancer H292 cells | N/A | N/A | Rac1/Cdc42 | Chaotham [ | ||
| Corosolic acid | Hepatocellular carcinoma cell lines (Huh7, HepG2 and Hep3B) | NOD/SCID mice | 5 mg/kg | Cdc42 | Ku [ | ||
| Gigantol | Human lung carcinoma cells NCI-H460 and NCI-H292 | N/A | N/A | Cdc42 | Charoenrungruang [ |
Figure 2The schematic of molecular mechanisms of Rho GTPases Rac and Cdc42, and relevant therapeutic natural compounds
During the osteoclastogenesis, after RANKL and RANK binding, the intracellular Rac1, Rac2 and Cdc42 are via GTP associate with podosomes regulation. However, these regulation effects might inhibited by various compounds (Left panel: inhibitory compounds for Rac1 and Rac2; Right panel: inhibitory compounds for Cdc42).